Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection

Li, Sen; Lan, Xiuwen; Gao, Hongyu; Li, Zhiguo; Chen, Li; Wang, Wenpeng; Song, Shubin; Wang, Yimin; Li, Chunfeng; Zhang, Hongfeng; Xue, Yingwei
December 2017
Journal of Cancer Research & Clinical Oncology;Dec2017, Vol. 143 Issue 12, p2455
Academic Journal
Purpose: Systemic Inflammation Response Index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, was recently developed and used as a marker to predict the survival of patients with malignant tumours. Cancer stem cells (CSCs) can contribute to gastric cancer progression and recurrence. It is not clear whether SIRI is associated with CSCs during gastric cancer development. Methods: The SIRI was developed in a training cohort of 455 gastric cancer patients undergoing curative resection between 2007 and 2009, and validated in a validation cohort of 327 patients from 2010 to 2011. CD44 + CSCs were measured on tumour sections by immunohistochemical analysis. Results: An optimal cut-off point for the SIRI of 0.82 divided the gastric cancer patients into a low SIRI group (SIRI < 0.82) and a high SIRI group (SIRI ≥ 0.82) in the training cohort. Compared with patients who had a SIRI < 0.82, patients who had a SIRI ≥ 0.82 had a shorter disease-free survival (DFS) (HR 2.529; 95% CI 1.922-3.326; p < 0.001) and shorter disease-special survival (DSS) (HR 2.692; 95% CI 2.022-3.585; p < 0.001) in the training cohort, comparable DFS and DSS findings were observed in the validation cohort, even for patients in pathological TNM stage of I subgroup. A SIRI ≥ 0.82 was significantly associated with older age, larger tumour, higher pathological TNM stage, lymphovascular invasion, and perineural invasion. Additionally, patients in the low SIRI group were prone to DFS and DSS benefits from postoperative adjuvant chemotherapy. Univariate and multivariate analyses revealed that SIRI was an independent predictor for DFS and DSS. Furthermore, gastric cancer patients with CD44 + CSCs scores had higher SIRI level (mean 1.198 vs. 0.835; p < 0.001). In patients with CD44 + CSCs, those with SIRI ≥ 0.82 had higher recurrence rates and shorter survival time than patients with SIRI < 0. 82. Conclusions: SIRI was a useful prognostic indicator of poor outcomes in patients with gastric cancer and is a promising tool for gastric cancer treatment strategy decisions. The dismal outcomes in patients with high SIRI might be related to CSCs.


Related Articles

  • A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Jeung, H.-C.; Rha, S. Y.; Shin, S. J.; Ahn, J. B.; Noh, S. H.; Roh, J. K.; Chung, H. C. // British Journal of Cancer;8/20/2007, Vol. 97 Issue 4, p458 

    Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status. In this paper, we describe the first study to evaluate S-1 monotherapy as an option for advanced gastric cancer patients who are...

  • Erratum to: Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients. Altini, Mattia; Carretta, Elisa; Morgagni, Paolo; Carradori, Tiziano; Ciotti, Emanuele; Prati, Elena; Garcea, Domenico; Amadori, Dino; Falcini, Fabio; Nanni, Oriana // Gastric Cancer;Jan2015, Vol. 18 Issue 1, p167 

    A correction to the article "Is a clear benefit in survival enough to modify patient access to the surgery service? A retrospective analysis in a cohort of gastric cancer patients" that was published in the previous issue is presented.

  • Carcinoma of stomach in Siyala governorate before and after 2003. AthabAlmissari, Ahmed M. // Tikrit Medical Journal;2013, Vol. 19 Issue 1, p142 

    Back ground: Gastric carcinoma it remains the leading cause of cancer death worldwide. There is marked geographical variation in incidence. Gastric cancer is more common in men and the incidence rises sharply after 50 years of age, the 5-year survival rate is 5 to 15%, More than 85% of gastric...

  • Incidence of metachronous gastric cancer in the remnant stomach after synchronous multiple cancer surgery. Nozaki, Isao; Hato, Shinji; Kobatake, Takaya; Ohta, Koji; Kubo, Yoshirou; Nishimura, Rieko; Kurita, Akira // Gastric Cancer;Jan2014, Vol. 17 Issue 1, p61 

    Background: In the preoperative evaluation for gastric cancer, high-resolution endoscopic technologies allow us to detect small accessory lesions. However, it is not known if the gastric remnant after partial gastrectomy for synchronous multiple gastric cancers has a greater risk for...

  • LAPAROSCOPIA DIAGNOSTICÄ‚ ÃŽN STRATEGIA DE STADIALIZARE ÅžI TRATAMENT A NEOPLASMULUI GASTRIC. Dan Togănel, Răzvan; Cazacu, Mircea; Muntean, Valentin // Clujul Medical;Mar2010, Vol. 83 Issue 1, p141 

    Introduction. The treatment of gastric cancer is conditioned by local, regional or sistemic extension. Pretherapeutic staging is sometimes innacurate, leading to useless laparotomies. Objectives. Within DIASTAL project (Diagnosis and Staging Laparoscopy in Abdominal Cancers) we have evaluated...

  • The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: A Meta-Analysis Including 14651 Patients. Deng, Kai; Yang, Li; Hu, Bing; Wu, Hao; Zhu, Hong; Tang, Chengwei // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Carcinoembryonic antigen (CEA) is commonly used as a serum tumor marker in clinical practice; however, its prognostic value for gastric cancer patients remains uncertain. This meta-analysis was performed to assess the prognostic value of CEA and investigate CEA as a tumor marker....

  • Lumboischialgia as the first sign of stomach cancer. Janković, Renata Ivanac; Šklebar, Duška; Klobučić, Mislav; `Šklebar, Ivan; Vrabec-Matković, Dragica // Medicinski Glasnik;Feb2012, Vol. 9 Issue 1, p128 

    The paper reports on a case of a seventy-threeyear- old male patient, whose disease was initially manifested by severe low back pain and lumboischialgia of the right leg as the first and only, and later, the leading symptom of disseminated adenocarcinoma of the stomach. The unusual presentation...

  • Prognostic Model Based on Systemic Inflammatory Response and Clinicopathological Factors to Predict Outcome of Patients with Node-Negative Gastric Cancer. Qu, Jing-lei; Qu, Xiu-juan; Li, Zhi; Zhang, Jing-dong; Liu, Jing; Teng, Yue-e; Jin, Bo; Zhao, Ming-fang; Yu, Ping; Shi, Jing; Fu, Ling-yu; Wang, Zhen-ning; Liu, Yun-peng // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Prognostic models are generally used to predict gastric cancer outcomes. However, no model combining patient-, tumor- and host-related factors has been established to predict outcomes after radical gastrectomy, especially outcomes of patients without nodal involvement. The aim of this study was...

  • Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. Fuse, Nozomu; Nagahisa-Oku, Emiko; Doi, Toshihiko; Sasaki, Takahide; Nomura, Shogo; Kojima, Takashi; Yano, Tomonori; Tahara, Makoto; Yoshino, Takayuki; Ohtsu, Atsushi // Gastric Cancer;Jul2013, Vol. 16 Issue 3, p324 

    Background: The Response Evaluation Criteria in Solid Tumors (RECIST) was revised in 2009, based on a large dataset of 6512 patients from 16 trials. However, no gastric cancer patients were included in those data. The purpose of this study was to clarify the difference between RECIST version 1.0...

  • Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil. Fanelli, Marcello F.; Silva, Milton J. B.; de Paiva, Jr., Tadeu F.; Chinen, Ludmilla T. D.; Guimarães, Andréa P. G.; Gimenes, Daniel L.; Pinheiro, Edilson D.; Rinck, Jr., José A.; Nicolau, Ulisses R.; Sanches, Solange M.; Melo, Celso A. L.; Dettino, Aldo L. A.; Cruz, Marcelo R. S.; de la Melo, Leila Maria M. P.; Formiga, Maria N. C.; de Lima, Vladmir C. C. // International Journal of Clinical Oncology;Aug2009, Vol. 14 Issue 4, p326 

    Gastric cancer is the second leading cause of death due to cancer worldwide and is particularly prevalent in Brazil. Promising new therapeutic agents have already shown activity in some gastrointestinal malignancies and their role in gastric cancer will need to be evaluated. Determining the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics